Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

Lemeng Zhang, Yongzhong Luo, Jianhua Chen, Tianli Cheng, Hua Yang, Changqie Pan, Haitao Li, Zhou JiangJournal of Oncology 2021 · DOI

TL;DR

This meta-analysis of real-world evidence confirms that afatinib is an effective and safe treatment for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, aligning with findings from randomized controlled trials. Importantly, it suggests that adjusting afatinib dosage based on patient tolerance may not compromise its efficacy.

What Problem Does This Paper Address?

Lung cancer remains a leading cause of cancer-related deaths globally. Non-small-cell lung cancer (NSCLC) accounts for the vast majority of these cases. A significant subset of NSCLC patients, particularly in Asian populations, harbor mutations in the epidermal growth factor receptor (EGFR) gene. These mutations drive tumor growth, making EGFR-tyrosine kinase inhibitors (TKIs) a standard first-line treatment. Afatinib, a second-generation EGFR-TKI, has shown promise in clinical trials. However, randomized controlled trials (RCTs) often have strict inclusion criteria that may not fully represent the diverse patient populations encountered in real-world clinical practice. Therefore, understanding afatinib's efficacy and safety in a broader, real-world setting is crucial. This paper aims to address this by conducting a meta-analysis of real-world evidence (RWE) to evaluate afatinib's performance and explore factors like dose adjustment, brain metastases, mutation type, and performance status.

Methods

The researchers conducted a meta-analysis of real-world studies. They systematically searched major databases (PubMed, Cochrane Library, Embase) for eligible studies published up to December 31, 2020. Inclusion criteria focused on studies involving patients with advanced, EGFR-mutated NSCLC who received afatinib and reported efficacy (ORR, DCR, OS, PFS, TTF) or safety data. Studies also needed to report differences based on specific patient subgroups (e.g., different afatinib doses, mutation types, ECOG-PS, brain metastases). To assess heterogeneity, they used Cochran's Q test and I² statistics, employing random-effects models when heterogeneity was significant and fixed-effects models otherwise. Publication bias was evaluated using Egger's test.

Datasets

The study utilized data from 25 real-world studies that met the inclusion criteria. These studies were published between 2014 and 2020 and primarily originated from Asia. Nine additional studies were included for qualitative descriptive analysis. No new datasets were introduced; the study synthesized existing RWE.

Key Insights and Ideas

  • Real-world validation: The study provides robust evidence from real-world data that afatinib is effective and safe for advanced NSCLC with EGFR mutations, mirroring findings from controlled clinical trials. This is crucial for generalizing treatment outcomes beyond the confines of RCTs.
  • Dose adjustment is viable: A key finding is that adjusting afatinib dosage based on patient tolerance (i.e., dose reduction) does not appear to significantly impact progression-free survival (PFS) or overall survival (OS). This supports a more personalized approach to treatment, aiming to improve patient tolerability without sacrificing therapeutic benefit.
  • Higher dose, better response: While dose adjustment doesn't harm PFS/OS, the study observed a significantly higher objective response rate (ORR) in patients receiving the full afatinib dose (40 mg/day) compared to those on a reduced dose. This suggests a trade-off between response rate and tolerability, where the full dose might be more potent in achieving tumor shrinkage.
  • Brain metastases as a factor: The presence of brain metastases was identified as a factor that can influence treatment outcomes, with patients without brain metastases showing potentially better PFS. This highlights the complexity of NSCLC treatment and the need to consider specific disease characteristics.

Key Results

  • Efficacy:
    • Disease Control Rate (DCR): 87.6%
    • Overall Response Rate (ORR): 58.9%
    • Median Progression-Free Survival (PFS): 12.4 months
    • Median Time to Failure (TTF): 15.4 months
    • Median Overall Survival (OS): 31.6 months
  • Safety (Incidences of Adverse Events):
    • Skin rashes: 71.4%
    • Diarrhea: 70.4%
    • Paronychia: 52.1%
    • Mucositis: 36.5%
  • Safety (Incidences of Severe Adverse Events - Grade ≥3):
    • Diarrhea: 9.7%
    • Skin rashes: 5.8%
    • Paronychia: 3.8%
    • Mucositis: 2.1%
  • Dose Adjustment: While PFS and OS were not significantly different between full-dose and non-full-dose groups, the ORR was significantly higher in the full-dose group (78.5%) compared to the non-full-dose group (67.8%).
  • Brain Metastases: Patients with brain metastases had a lower median PFS compared to those without.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small sample size in some studies: This could impact the reliability of certain outcome indicators.
  • Methodological quality assessment: The lack of suitable quality evaluation tools for RWE studies made it difficult to assess the impact of study quality on the results.
  • Limited subgroup analysis: Direct comparisons between different generations of EGFR-TKIs (e.g., afatinib vs. erlotinib, dacomitinib, gefitinib) were not performed within this meta-analysis.

Future work could focus on addressing these limitations by including larger RWE datasets and developing better tools for assessing RWE quality. Further investigation into the specific impact of uncommon EGFR mutations and the optimal management of brain metastases in the context of afatinib treatment would also be valuable.

Summary updated

Abstract

The efficacy and safety of afatinib has been confirmed by real-world evidence in advanced NSCLC with EGFR mutation, consistent with randomized controlled trial results. In real-world setting, tolerability-guided dose adjustment might not affect the afatinib efficacy.
BibTeX
@article{zhang2021efficacy,
  author = {Lemeng Zhang and Yongzhong Luo and Jianhua Chen and Tianli Cheng and Hua Yang and Changqie Pan and Haitao Li and Zhou Jiang},
  title = {{Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence}},
  journal = {Journal of Oncology},
  year = {2021},
  doi = {10.1155/2021/8736288},
}
Figure